Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
BLINK AG currently manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area, featuring 2 pending office actions. These actions are spread across 2 distinct examiners and 2 distinct art units, which suggests a breadth of technical claims that require oversight from different specialized groups at the USPTO. This arrangement necessitates a strategy that can adapt to the varying perspectives of 2 distinct examiners.
The busiest examiner for the portfolio is PARISI, JESSICA DANIELLE, who is currently managing 1 pending office action. Although the total volume of 2 pending office actions is low, the involvement of 2 distinct art units indicates that the portfolio is being tested against different sets of prior art or technical standards. Practitioners should balance their approach between the specific requirements of PARISI, JESSICA DANIELLE and the other examiner involved to ensure consistency across the Biotechnology & Pharmaceuticals filings. With 2 pending office actions, the ability to harmonize arguments across 2 distinct art units is essential for maintaining a cohesive portfolio strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPPE, EMMA RUTH | 1 | 42.1% | +56.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786033 | A METHOD OF DETECTING AND/OR QUANTITATING AN ANALYTE OF INTEREST IN A PLURALITY OF BIOLOGICAL LIQUID SAMPLES | HOPPE, EMMA RUTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786033 | A METHOD OF DETECTING AND/OR QUANTITATING AN ANALYTE OF INTEREST IN A PLURALITY OF BIOLOGICAL LIQUID SAMPLES | HOPPE, EMMA RUTH | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17786033 | A METHOD OF DETECTING AND/OR QUANTITATING AN ANALYTE OF INTEREST IN A PLURALITY OF BIOLOGICAL LIQUID SAMPLES | HOPPE, EMMA RUTH | 1683 | §103§112Other | Final Rejection | — | Pending | Jun 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial